Clinical Trials Search
A Phase 1 Study of CG0070 Combined with Nivolumab in Cisplatin Ineligible Patients with Muscle Invasive Bladder Cancer (MIBC)
Investigators aim to evaluate the safety and efficacy of combination neoadjuvant therapy using intravesical CG0070 and IV Nivolumab in cisplatin ineligible patients with MIBC.
To evaluate the safety of combination therapy using intravesical CG0070 and IV nivolumab according to Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5.0). To assess the changes in the inflammatory status of the tumors after combination therapy
BMS-936558 (Nivolumab); CG0070 (); DDM (); Nivolumab (Opdivo)